Spain’s Insud lifts bar to its NuvaRing rival

Insud Pharma and its Exeltis subsidiary have succeeded in removing a injunction preventing the Spanish firm from marketing locally its Ornibel (ethinylestradiol/etonogestrel) alternative to Merck, Sharp & Dohme’s (MSD’s) NuvaRing.